Skip to content

Author

T. Shibuki

We have 2 of 147 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Relationship between initial dose, dose intensity, and survival in unresectable pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil, and folinic acid

Reduced starting dose and RDI <80% were not associated with inferior survival, suggesting that individualized dose modification may be feasible, and future prospective studies are warranted to refine NFF dosing strategies.

Y. Ueda, Hiroki Taguchi, Mototsugu Shimokawa et al. · 0 citations
Review Open access Jul 2026

AI-integrated multi-omics platform to revolutionize anti-metastatic therapy development through circulating tumor cell profiling: SCRUM-MONSTAR-CTC

It is proposed that the next phase of precision oncology should integrate the cellular dimension of metastasis through systematic circulating tumor cell (CTC) profiling and highlights adherent-to-suspension transition (AST) as one representative, experimentally tractable plasticity program that enables tumor cells to s...

T. Hashimoto, T. Shibuki, T. Fujisawa et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.